Core Insights - Wellgistics Health, Inc. (NASDAQ: WGRX) is set to appear live on YouTube on July 22, 2025, at 1:00 PM EST to discuss its recent performance and future strategy [1][2] Group 1: Company Overview - CEO Brian Norton will lead an unfiltered discussion on WGRX's recent momentum, stock performance, and market outlook [2] - The company is recognized for its role in pharmaceutical distribution and healthcare technology [1] Group 2: Event Details - The live session will be hosted on the Floorstocks channel, which focuses on amplifying rising public companies [2][4] - Retail investors will have the opportunity for direct engagement during the session [2] Group 3: Strategic Insights - The discussion will cover WGRX's disruptive strategy in healthcare distribution and direct-to-patient services [5] - WGRX is integrating XRP blockchain payments into healthcare transactions to enhance efficiency and global accessibility [5] - The session will analyze the recent surge in stock activity and market dynamics [5]

Core Insights - Telix Pharmaceuticals reported a significant increase in Q2 2025 revenue, reaching approximately $204 million, a 63% increase year-over-year, and reaffirmed its FY 2025 revenue guidance of $770 million to $800 million [3][6][22]. Financial Performance - Group revenue for Q2 2025 was $204 million, compared to $125 million in Q2 2024, marking a 63% increase. Revenue for Q1 2025 was $186 million, showing a 10% increase quarter-over-quarter [3][6]. - Global Illuccix® revenue was $154 million in Q2 2025, up 25% from $123 million in Q2 2024, and slightly increased by 2% from $151 million in Q1 2025 [3]. - RLS revenue reached $46 million in Q2 2025, with no revenue reported in Q2 2024, and a 39% increase from $33 million in Q1 2025 [3]. Business Highlights - Dose volumes for Illuccix rose 7% quarter-on-quarter in the U.S., indicating strong market demand despite competitive pricing pressures [4]. - The launch of Gozellix in the U.S. has commenced, with the product assigned a Level II HCPCS code, a key step towards reimbursement [6]. - The ProstACT Global Phase 3 trial achieved a milestone with all 30 patients consented for Part 1, and the trial is expanding into China, Japan, and Canada [7]. Therapeutics Development - TLX591 (Lu-rosopatamab tetraxetan) is progressing in its Phase 3 trial, with dosing completed for patients in two of the three arms [7]. - TLX592 (Ac-PSMA-RADmAb) has submitted an application for a Phase 1 study in Australia [7]. - TLX101 (I-iodofalan) received HREC approval in Australia for an international pivotal trial [7]. - TLX250 (¹⁷⁷Lu-DOTA-girentuximab) is enrolling patients in a Phase 1b/2 clinical trial for clear cell renal cell carcinoma [7]. Regulatory and Corporate Updates - Telix is cooperating with the U.S. SEC regarding a subpoena for documents related to its prostate cancer therapeutic candidates [11][12]. - The company has received country-level approvals for Illuccix in multiple European countries and is launching on a market-by-market basis [13]. - Telix has completed enrollment for the Illuccix China Phase 3 study, aiming for marketing authorization in Q4 2025 [13]. Manufacturing and R&D - Telix announced a GMP manufacturing facility in Yokohama, Japan, enhancing its global manufacturing strategy [14]. - The TMS facility in Brussels South, Belgium, has produced its first GMP commercial radiopharmaceutical doses [14]. - The company expects a 20% to 25% increase in R&D expenditure for FY 2025 compared to FY 2024 [22].

AstraZeneca on Monday said it plans to invest $50 billion in bolstering its U.S. manufacturing and research capabilities by 2030, becoming the latest pharmaceutical firm to ramp up its stateside spending in the wake of U.S. trade tariffs.The Anglo-Swedish biotech company, which is headquartered in Cambridge, England, said the "cornerstone" of the commitment would be a new multi-billion dollar facility to produce its weight management and metabolic portfolio, including its oral GLP-1 obesity pill.The facilit ...

Sanofi agrees to buy UK vaccine developer Vicebio for as much as $1.6 billion, as it seeks to expand in respiratory treatments https://t.co/02refS9TM7 ...

Some believe that the president’s ill-defined pharma-tariff timeline is a sign he is not serious. For now, that seems like wishful thinking https://t.co/SteUAqSZke ...

【 导读 】 2025年7月22日，中国资本市场这片热土上，一块名为"科创板"的"试验田"已悄然耕耘六载 春秋。6年，是筚路蓝缕的创业史，是硬核科技的淬炼场，更是创新驱动国家战略的生动注 脚。589颗"科创之星"在此汇聚，闪耀着7.3万亿市值的磅礴光芒，它们从核心技术"卡脖 子"的困境中破土，在新质生产力的浪潮里拔节，共同编织着中国产业升级与科技自立自强的 宏大叙事。 值此承前启后的重要时刻，我们特别邀约了数位深耕于科创板沃土的领航者——他们是前沿 赛道的开拓者，是实验室到生产线奇迹的缔造人。褪去资本市场的喧嚣，这些掌舵人欣然提 笔，以最真挚的笔触，为我们留下了属于这个时代的"科创心语"。此刻，让我们一同静心聆 听，这些搏击于时代潮头的灵魂之声，如何汇成推动中国科创巨轮驶向星辰大海的澎湃涛 声。 海光信息总经理沙超群 正逢科创板开市 六 周年，海光信息也即将上市满 三 年。科创板为科 技企业提供了一个更加开放、包容、高效的资本市场环境，得益于科 创板丰沃的投融资土壤以及政策 " 工具箱 " ，海光信息近年来不断在 公司治理能力、创新能力、竞争能力和经营能力上取得显著进展。 海光在芯片市场取得的长足发展，离不开 ...

Yuting Yang +852-2978-7283 | yuting.y.yang@gs.com 21 July 2025 | 8:00PM HKT China Matters Waiting for the Slowdown (Shan) Andrew Tilton +852-2978-1802 | andrew.tilton@gs.com Goldman Sachs (Asia) L.L.C. Hui Shan +852-2978-6634 | hui.shan@gs.com Goldman Sachs (Asia) L.L.C. Lisheng Wang +852-3966-4004 | lisheng.wang@gs.com Goldman Sachs (Asia) L.L.C. Xinquan Chen +852-2978-2418 | xinquan.chen@gs.com Goldman Sachs (Asia) L.L.C. Waiting for the Slowdown (Shan) Despite external tariff turbulences and ongoing stru ...

Core Viewpoint - A class action lawsuit has been filed against UroGen Pharma Ltd. for alleged misleading statements regarding its lead product UGN-102, which is intended for treating low-grade intermediate risk non-muscle invasive bladder cancer [1][2]. Group 1: Lawsuit Details - The lawsuit covers investors who acquired UroGen securities between July 27, 2023, and May 15, 2025, with a deadline of July 28, 2025, to apply as lead plaintiff [1]. - Allegations include that UroGen's ENVISION clinical study for UGN-102 was inadequately designed, lacking a concurrent control arm, which undermined the evidence of effectiveness [3]. - The FDA had previously warned UroGen about the study design, suggesting a randomized trial, which UroGen did not conduct [4]. Group 2: Stock Price Impact - Following the FDA's briefing document on May 16, 2025, which raised concerns about the study's interpretability, UroGen's stock price fell nearly 26% [4]. - On May 21, 2025, after the Oncologic Drugs Advisory Committee voted against the approval of UGN-102, the stock price dropped nearly 45% [5].

AstraZeneca plans to invest $50 billion in the US before 2030, ratcheting up spending in the country ahead of potential tariffs on imported medicines https://t.co/zu0W9NjXEu ...

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for allegedly misleading investors regarding the viability of its drug candidates, particularly troriluzole and BHV-7000, during the period from March 24, 2023, to May 14, 2025 [1][2]. Group 1: Company Overview - Biohaven Ltd. is a biopharmaceutical company focused on developing therapies in immunology, neuroscience, and oncology [1]. - The company is working on several product candidates, including troriluzole for spinocerebellar ataxia (SCA) and BHV-7000 for bipolar disorder [1]. Group 2: Allegations and Legal Proceedings - The lawsuit alleges that Biohaven overstated the regulatory prospects and data sufficiency for troriluzole's approval for SCA [2]. - It is also claimed that the efficacy and clinical prospects of BHV-7000 for bipolar disorder were similarly overstated [2]. - The complaint suggests that the revelation of these issues could significantly negatively impact Biohaven's business and financial condition [2]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers by September 12, 2025 [3]. - Participation in the class action is not required to be eligible for recovery; shareholders can remain absent class members if they choose [3].